계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
VectivBio
About
VectivBio is a biotechnology company committed to making a difference in the lives of patients suffering from serious rare diseases.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $35M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2019
- Number Of Employee
- 51 - 100
- Operating Status
- Active
VectivBio is a clinical-stage biotechnology company bringing transformational medicines to patients with serious rare diseases. They are committed to pursuing rare diseases with well-defined biology that can be targeted with best-in-disease therapies that have the potential to meaningfully transform and improve the lives of patients and their families, not just provide an incremental improvement or benefit over the standard-of-care.It was founded as a spinout from Therachon, a biotechnology company acquired by Pfizer for its program in achondroplasia. VectivBio was incorporated in 2019 and is based in Basel, Switzerland.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 30, 2022 | Post-IPO Debt | $75M | 1 |
Kreos Capital
|
— | Detail |
| Oct 19, 2020 | Series Unknown | $110M | 2 | — | — | Detail |
| Jan 8, 2020 | Series A | $35M | 2 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Kreos Capital
|
Yes | Post-IPO Debt |
Inserm Transfert Initiative
|
— | Series Unknown |
Versant Ventures
|
— | Series Unknown |
